Drug intelligence / Profile preview

KAT-009

Development stage: Preclinical
Lead developer: New G Lab Pharma
Modality: Small Molecules

Overview

KAT-009 is a small molecule anticancer therapeutic being developed by NewG Lab Pharma. It is designed to target the Warburg Effect, a metabolic hallmark of cancer where cells preferentially utilize aerobic glycolysis for energy production even in the presence of oxygen. By targeting this metabolic vulnerability, KAT-009 aims to disrupt the energy production and survival of cancer cells. The drug is currently in the preclinical stage of development, with a primary focus on the treatment of glioblastoma, an aggressive form of brain cancer.

Beyond the preview

Go deeper on KAT-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAT-009.

Explore the full profile